ArticleMikrochimica acta2026
An integrated system of micromixers and microfluidic concentration gradient chips assisted drug screening over large concentration range.
Article in Mikrochimica acta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
There is an unmet need for a versatile platform that enables flexible multi-drug combination screening with a wide concentration range and automated operation. Accordingly, an automated multi-drug combination screening platform (ISMMCGs) integrating elliptical baffle micromixers (EBMixers) and three types of microfluidic concentration gradient (MCG) chips was developed. The EBMixer achieves > 90% mixing efficiency within a 40 mm channel (Re = 0-70), ensuring rapid uniform mixing. The MCG chips (linear, two-fold, ten-fold dilution), designed via the equivalent circuit method, spanning a four-order-of-magnitude concentration gradient (10⁻⁴-1). Automated switching via a micro-solenoid valve array enables "rough/fine/precise" screening. Validation with sodium fluorescein confirms gradient reliability; Screening experiments of vancomycin against MRSA demonstrate that this system can narrow the OD600-determined apparent MIC range down to 0.78-1.01 µg/mL, verifying the application potential of this platform in rapid screening of antimicrobial concentration ranges; and tigecycline-colistin sulfate combination screening for MDR-AB verifies the platform's flexibility for concentration-dependent combinatorial testing. This integrated platform addresses the limitations of traditional methods by balancing wide concentration coverage, multi-drug flexibility, and automation. It provides a refined, cost-effective tool for drug screening, facilitating the development of personalized treatment regimens and accelerating drug discovery processes, with broad applications in antimicrobial resistance research and pharmaceutical development.
Indexed as
Identifiers
42471438What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.